GlaxoSmithKline Pharmaceuticals announced its financial results for the second quarter of fiscal year 2025. The board approved an investment of ₹1.74 crores in a solar power project at the Nashik plant under a group captive mechanism. The company’s financial results statement, both standalone and consolidated, have been released, marking a period of significant decisions and financial reporting.
Financial Performance
GlaxoSmithKline Pharmaceuticals has released its unaudited standalone and consolidated financial results for the second quarter (Q2: July-September) and half-year ended September 30, 2025. The results were approved by the Board of Directors at a meeting held on November 6, 2025.
Key Financial Figures (Standalone – ₹ in Lakhs)
- Revenue from operations: ₹97,363
- Total Income: ₹100,490
- Profit before tax: ₹35,065
- Profit for the period: ₹25,500
Key Financial Figures (Consolidated – ₹ in Lakhs)
- Revenue from operations: ₹97,994
- Total Income: ₹101,351
- Profit before tax: ₹35,400
- Profit for the period: ₹25,749
Investment in Solar Power
The Board of Directors has approved an investment of ₹1.74 crores for a solar power project at the company’s Nashik plant. This project will operate under a Group Captive mechanism, aiming to meet green energy needs and optimize energy costs.
Clean Max Galapagos Investment Details
The investment is made in Clean Max Galapagos Private Limited, a special purpose vehicle (SPV) set up to supply 4.95 MWp capacity to GlaxoSmithKline Pharmaceuticals to meet their renewable energy requirements in Maharashtra. GSK is acquiring 26% of the shareholding/control.
Clean Max Galapagos Financials
Clean Max Galapagos Private Limited was incorporated on May 21, 2024. As a newly incorporated SPV, there is no turnover history for the last three years.
Source: BSE
